Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalCCEL +6.22%57 3-Year EBITDA Growth Rate is -44.20% as of May. 2026. GuruFocus rates CCEL with a GF Score™ of 57/100 and a GF Value™ of $5.44 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 95.44% on this metric.
During the past 12 months, Cryo-Cell International's average EBITDA Per Share Growth Rate was -85.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -44.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cryo-Cell International was 375.20% per year. The lowest was -60.50% per year. And the median was 2.85% per year.
Cryo-Cell International (AMEX:CCEL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cryo-Cell International 3-Year EBITDA Growth Rate Related Terms
CCEL vs EHSI, PIII, CCM: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's 3-Year EBITDA Growth Rate falls into.
Cryo-Cell International 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -44.20% mean?
Cryo-Cell International (CCEL) has a 3-Year EBITDA Growth Rate of -44.20% as of May. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cryo-Cell International and its competitors. According to the industry distribution chart, Cryo-Cell International ranks #502 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 95.4%.
Is Cryo-Cell International's 3-Year EBITDA Growth Rate too high?
Cryo-Cell International's current 3-Year EBITDA Growth Rate is -44.20%. Based on the distribution chart, Cryo-Cell International ranks #502 out of 526 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's 3-Year EBITDA Growth Rate compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #502 out of 526 companies for 3-Year EBITDA Growth Rate. This places Cryo-Cell International in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current 3-Year EBITDA Growth Rate is -44.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.44, compared to a current price of $3.93 — trading 27.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -44.20%. Cryo-Cell International's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current 3-Year EBITDA Growth Rate is -44.20% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (CCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of $3.93 is trading 27.8% below its estimated GF Value™ of $5.44.
GuruFocus considers Cryo-Cell International to be Modestly Undervalued.
Key valuation signals for CCEL:
3-Year EBITDA Growth Rate: -44.20%
GF Value™: $5.44 vs. price of $3.93 (27.8% below fair value)
No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
57GF Score
Get the complete analysis for CCEL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCEL has been successfully added to your 
